iPS Cell – Page 31

Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness

Post author:
Post published:September 12, 2024
Post category:

Therapeutic Candidate or Device The therapeutic candidate is a patient specific (autologous) induced pluripotent stem cell derived retinal pigment epithelium (AiPSC-RPE) product. Indication AiPSC-RPE cell product will be indicated for…

Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease

Post author:
Post published:September 12, 2024
Post category:

Therapeutic Candidate or Device Allogeneic iPSC derived dopamine progenitors delivered to the brain of Parkinson's disease patients Indication Idiopathic Parkinson's disease Therapeutic Mechanism The cellular product reconstitutes dopaminergic neuron circuits…

IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell

Post author:
Post published:September 12, 2024
Post category:

Therapeutic Candidate or Device FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell Line Indication FT516 monotherapy for patients with advanced cancer and…

Subscribe to Receive CIRM News